Xeris Biopharma Holdings (FRA:2B30) 6-Month Share Buyback Ratio : -0.33% (As of Dec. 2024 )

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Xeris Biopharma Holdings's current 6-Month Share Buyback Ratio was -0.33%.

Competitive Comparison of Xeris Biopharma Holdings's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, Xeris Biopharma Holdings's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Xeris Biopharma Holdings 6-Month Share Buyback Ratio Calculation

Xeris Biopharma Holdings's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(148.937	-	149.429)	/	148.937
	=	-0.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings (FRA:2B30) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Xeris Biopharma Holdings 6-Month Share Buyback Ratio Related Terms

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

XERS:USA 0A8E:UK

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Xeris Biopharma Holdings Headlines

No Headlines